Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive, 1 fatal disorder, caused by mutations in the dystrophin gene, which affects approximately 1 in 3600-6000 live male births worldwide. [2] [3] [4] Deletion mutations, which are the most common cause of DMD, 5 alter the open reading frame of the dystrophin gene and usually result in a complete absence of the protein. 6, 7 Dystrophin protein is an important structural component of muscle fibers connecting their cytoplasmic cytoskeleton to the membrane-bound dystroglycan complex, [8] [9] [10] [11] which in turn binds to laminin in the extracellular matrix. [9] [10] [11] The lack of a functional dystrophin protein in muscle leads to destabilization of the sarcolemmal membrane, causing muscle fiber degeneration and necrosis. 12, 13 Over time, skeletal muscle tissue in DMD patients is replaced with fat and connective tissue. Despite extensive research to date, currently there is no cure for this disease.
Gene replacement has potential utility in the treatment of single-gene disorders, such as DMD. Dystrophin cDNA transfer using viral vectors for delivery has been extensively tested for therapeutic efficacy in the mdx mouse, a genetic and biochemical model of DMD. 6, 14 Recently, the first studies of gene replacement for muscular dystrophy in human patients were reported. 15 As the dystrophin gene is very large with 11 kb of coding sequence, transfer of the full-length dystrophin cDNA into muscles of dystrophic mice was only possible due to the development of gutted or high-capacity adenoviral (HC-Ad) vectors, which retain no viral genes and thus have a large capacity for an inserted DNA expression cassette. [16] [17] [18] The lack of viral genes in the HC-Ad vector leads to a lower induction of anti-vector immunity than previous generation Ad vectors and has also been shown to facilitate prolonged dystrophin protein expression in mouse models of DMD. 16 However, in the case of a disease such as DMD, in which the endogenous therapeutic protein can be largely absent in the host, the immunological barrier to a successful gene transfer is not limited to the host immune reaction to vector particles, but also to the transferred therapeutic gene product. [19] [20] [21] Previous studies found that anti-dystrophin antibodies were induced by HC-Ad vector-mediated dystrophin cDNA delivery to muscles of adult mdx mice as early as 2 weeks after gene transfer. 21 The response of the host immune system to the transferred gene reflects the normal function of the host defense system against neoantigens. This anti-dystrophin immunity is detected despite the rare dystrophin-expressing revertant fibers that are found in mdx muscle. [22] [23] [24] [25] However, very little is known about the anti-dystrophin immune response raised by dystrophin-deficient recipients to dystrophin gene transfer.
Therefore, we investigated the anti-dystrophin immune response by manipulating the immune system of adult mdx mice through a temporal removal of immune cells before vector-mediated murine dystrophin cDNA delivery. We utilized complementary approaches to temporarily remove the host immune system before gene transfer. In the first set of experiments, a low dose of irradiation was administered to deplete only the peripheral immune cells of adult mice and was followed by self-reconstitution of the host's peripheral immune cells after gene transfer. In the second set of experiments, a high dose of irradiation was administered before gene transfer. After gene delivery, the host central and peripheral immune system was reconstituted by bone marrow (BM) transfer from a syngeneic wild-type donor; this BM should comprise cells that are fully tolerant to dystrophin protein. By employing the two different doses of irradiation, we explored the relative contributions of the peripheral and central components of the immune response to recombinant murine dystrophin. We determined whether the returning or new host immune cells recognized the full-length murine dystrophin protein as a self-protein. We further explored the role of regulatory T (Treg) cells [26] [27] [28] [29] [30] in the peripheral and central immune response to recombinant, murine dystrophin protein.
Results

Low-dose irradiation delays or eliminates anti-dystrophin humoral response
We first examined the effect of a sublethal 600 rad dose of whole-body irradiation of 6-week-old mdx mice intended to temporarily remove peripheral immune cells. Immune responses against HC-Ad vector-mediated murine dystrophin expression in dystrophic muscles was studied longitudinally. A control group was not irradiated before gene delivery. Within 24 h, post-irradiation mice in both groups each received an intramuscular injection of HC-Ad vector carrying the murine dystrophin cDNA driven by the MCK promoter (1.5-2.0 Â 10 10 genome copies in each tibialis anterior (TA) muscle). The treated and control mice were analyzed at 4, 8 and 12 weeks after irradiation and gene delivery.
At 4 weeks after gene transfer, mdx mice that had been irradiated before vector injection had no detectable antidystrophin humoral response (Figure 1a , week 4), whereas control mice demonstrated an anti-dystrophin humoral response at 4 weeks after treatment (Figure 1a , week 4). At 8 weeks after vector transfer, the irradiated mdx mice demonstrated a variable level of anti-dystrophin humoral immunity. Three of the five mice showed a dystrophin-specific humoral response and two mice showed no response to dystrophin protein. The level of the response in mice that did produce anti-dystrophin antibodies was lower compared with control mice, all of which demonstrated a dystrophin-specific humoral response (Figure 1a , week 8). A third group of mice was analyzed at 12 weeks after vector injection. One of the four irradiated mice produced an anti-dystrophin humoral response, whereas the other three mice did not (Figure 1a , week 12). All control mice showed a dystrophin-specific humoral response at 12 weeks ( Figure 1a and Table 1 ).
HC-Ad vector-mediated dystrophin expression in low-dose irradiated mdx muscles
Dystrophin expression in the vector-injected muscles of mdx mice was analyzed by immunostaining of muscle Figure 1 The anti-dystrophin humoral response and loss of muscle dystrophin expression was delayed in mdx mice treated with lowdose irradiation followed by dystrophin gene transfer using a highcapacity adenoviral vector. (a) Sera from mdx mice that were irradiated at 600 rad and received an intramuscular injection of dystrophin vector (IR+DYS), received an intramuscular injection of dystrophin vector without irradiation (no IR+DYS), or received neither irradiation nor dystrophin vector (untreated mdx) were incubated with membrane-immobilized dystrophin protein. Sera were collected for analysis at 4, 8 and 12 weeks (Wk) after treatment (n ¼ 6 for week 4 and n ¼ 5 for weeks 8 and 12) . No serum indicates a negative immunoblotting control without mouse serum primary antibody. DYS-2 indicates a positive immunoblotting control using a monoclonal anti-dystrophin antibody as the primary antibody. Figure  1b and Table 1 ). The number of dystrophin-expressing muscle fibers in the irradiated, vector-treated mice decreased with time correlating temporally with the production of anti-dystrophin antibodies (Figure 1b ). The reduction in the number of dystrophin-expressing fibers over time was observed even in mice that did not produce anti-dystrophin antibody, suggesting that the humoral response was not solely responsible for the decrease in dystrophin protein expression.
Lymphocytes in draining lymph nodes and vector-injected muscle after low-dose irradiation
As antibody production and B-cell population are directly related to each other, B-cell levels in the lymph nodes draining the vector-injected TA muscles were analyzed to ensure that the peripheral B cells in the irradiated mice had returned to levels comparable to untreated mdx mice. At all three time points, the level of B cells, which were identified by CD19 expression, in draining lymph nodes of vector-treated mice was not significantly different from untreated mdx mice, suggesting a return to the full complement of B cells after irradiation (Figure 2a ). The number of B cells in the irradiated, vector-treated mice, however, increased gradually from weeks 4 to 12. The increase in the number of B cells coincided with the development of anti-dystrophin antibodies, suggesting that the self-reconstituted B cells eventually recognized dystrophin protein as a neoantigen and generated an anti-dystrophin immune response. At 4 weeks after treatment, the number of B cells in the draining lymph nodes of the control mice was significantly higher than both the irradiated, vectorinjected and the untreated groups (Figure 2a ), suggesting an early vector-mediated B-cell expansion that correlated with the high level of anti-dystrophin humoral response observed in control mice. We also investigated the infiltration of CD4 + and CD8 + T cells in vector-injected muscles of mdx mice to assess the cellular immune reaction following murine dystrophin expression. As muscle infiltration of CD4 + and CD8 + T cells is a disease-associated phenotype of mdx mouse muscle and is thought to promote muscle fiber necrosis, 31 infiltrating T cells are seen in dystrophic mdx muscles with and without dystrophin gene transfer. We compared the number of T cells infiltrating vectorinjected muscle, with or without irradiation, with age-matched untreated muscle.
Levels of infiltrating CD4 + and CD8 + T cells in muscles of low-dose irradiated, vector-treated or control mice were not significantly different from untreated mice at week 4 after treatment (Figure 2b and c). At week 8, CD4 + and CD8 + T cells increased in the vector-injected TA muscles of both irradiated and nonirradiated hosts compared with untreated muscle, indicating the development of a T cell-mediated response following dystrophin vector expression that was not affected by irradiation (Figures 2b and c) . By week 12, levels of CD4 + and CD8 + T cells had increased in all groups to similar levels (Figures 2b and c) .
The pattern of T-cell infiltration for both CD4 + and CD8 + T cells observed on muscle sections was consistently different in the vector-treated, irradiated mice compared with the control group (Figure 3 ). At week 4, T cells were scattered throughout the muscle tissue in irradiated, vector-injected mdx muscles, similar to those in age-matched untreated mdx muscles. In the control group, however, in addition to scattered infiltrating cells, large numbers of cells were seen to cluster around one or multiple adjacent fibers, and groups of necrotic muscle fibers were seen as early as 4 weeks after treatment. Therefore, it appeared that the transduced muscle fibers were targeted by a specific cell-mediated host immune response in the absence of irradiation before gene transfer. In the irradiated group, a similar pattern was only seen in the vector-injected muscles at week 12 after treatment (data not shown).
High-dose irradiation delays anti-dystrophin humoral response
We next examined the effect of removing central and peripheral immune cells of mdx mice by 900 rad irradiation before intramuscular dystrophin gene delivery (1.5 Â 10 10 genome copies in each TA muscle). The immune systems of irradiated mice were then reconstituted by transfer of wild-type BM from C57BL/10 (B10) donors. Mice were analyzed at 4, 8 or 12 weeks after treatment. We had two control groups: one that underwent only gene delivery without receiving other Table 1 Summary of humoral immune response and dystrophin expression data in low-and high-dose irradiated groups IR (600 rad)+DYS IR (900 rad)+DYS+B10 BM IR (900 rad)+B10 BM only No IR+DYS Untreated DYS+fibers Wk 4 (+ + + + + ±) ( + + + ± ±) ( À À À) ( À À À) ( À À À) Wk 8 (+ + + ± ±) ( + + + ± ±) ( À À À) ( À À À) ( À À À) Wk 12
(+ + ± ± ) ( + ± ± ± ± ) ( À À ± ) ( À À À) ( À À À)
Anti-DYS Ab Wk 4 (À À À À À À) ( À À À À À) ( À À À) (+ + +) (À À À) Wk 8
(À À À ± +) (À À À À À) ( À À À) (+ + +) (À À À) Wk 12
(À À À +) (+ + + + +) (À À À) (+ + +) (À À À) treatments and one that was irradiated and received adoptive transfer of B10 BM without gene transfer (Table 1) . We considered what would be an expected time course to clear the initial load of vector capsid proteins. To explore this experimentally, C 2 C 12 myoblast cells were infected in vitro with Ad vector. Harvested cell samples at various time points for 48 h were assayed for Ad vector capsid proteins by western blot. Nearly all Ad capsid proteins were degraded in vitro by 12-24 h after infection (data not shown). Despite likely differences At 4 weeks after gene transfer, none of the mice that had been irradiated and received B10 BM produced anti-dystrophin antibodies. However, the vector-injected mice that had not been irradiated produced antidystrophin antibodies at this time point, similar to the control group in the low-dose irradiation study (Figure 4a ). Unlike the low-dose study group, in which a few mice produced anti-dystrophin antibodies at week 8 after treatment, at this time point none of the irradiated, vector-injected mice that received B10 BM produced an anti-dystrophin humoral response (Figure 4a ). By 12 weeks after treatment, however, we observed anti-dystrophin humoral response in all of these mice (Figure 4a ).
HC-Ad vector-mediated dystrophin expression in high-dose irradiated mdx muscles
Dystrophin protein expression in the muscles of treated mdx mice was assessed by immunohistological assay, as before. In the high-dose irradiation group, we first determined that adoptive transfer of B10 BM alone did not give rise to dystrophin-expressing fibers above the level in untreated age-matched mdx muscles, for at least 12 weeks after treatment (Figure 4b ). At all time points after treatment, dystrophin expression was significantly higher in the muscles of the irradiated mice that had received vector and B10 BM compared with the control groups (Figure 4b, week 4) . Compared with week 4, at week 8 after treatment, the level of dystrophin expression increased in B10 BM recipient mice that received dystrophin vector (Figure 4b; week 8 ). The subsequent decline in dystrophin expression level at week 12 after treatment correlated with the production of anti-dystrophin antibodies by these mice.
Lymphocytes in the host lymph nodes and vector-injected muscles after high-dose irradiation and BM transfer
The lymph nodes draining vector-treated muscles of the high-dose irradiated mice were analyzed to examine peripheral lymphocyte levels. The percentage of B cells in the draining lymph nodes was similar among all groups at 4 and 8 weeks after treatment (Figure 5a ). By week 12 after treatment, the B cell levels in all groups had decreased (Figure 5a , week 12).
We also looked at T-cell infiltration in the treated muscles at the same time points. At week 4 after treatment, the number of CD4 + T cells was significantly lower in the muscles of the irradiated mice that received dystrophin vector and B10 BM compared with the nonirradiated, vector-injected mice (Figures 5b and c) . CD8 + T cells were at comparable levels in the irradiated and nonirradiated, vector-injected mice. Starting at week 8, however, muscle infiltrating CD4 + and CD8 + T cells increased in the irradiated, vector-injected mice at comparable levels to the nonirradiated, vector-injected mice (Figures 5b and c) . The levels of infiltrating CD4 + and CD8 + T cells remained stable at week 12 after treatment compared with week 8 in the irradiated, vector-injected group that received B10 BM (Figures 5b  and c ).
Infiltrating T cells were observed scattered throughout in the high-dose irradiated, vector-injected muscles at all time points (data not shown) in contrast to clustering around specific muscle fibers in nonirradiated, vector-injected muscle (Figure 3 ). These observed differences in the pattern of muscle T-cell infiltration Dystrophin gene transfer to irradiated mdx mice S Eghtesad et al was similar to that observed in the low-dose irradiation study.
Treg cells in treated muscles
An important cell population in modulating immunity is a regulatory subset of CD4 + T cells expressing the fork head box 3 (Foxp3) transcription factor, commonly referred to as Foxp3 + Treg cells. 30, 32, 33 We compared the infiltration of Treg cells in treated muscles at each time point to explore a possible role of these cells in modulating the immunity that we observed in treated mdx mice. In the low-dose irradiation study, the number of muscle-infiltrating Treg cells was comparable at each time point for the vector-treated groups with and without irradiation (Figure 6a ). In the high-dose irradiation study, there was a significant increase in Treg-cell infiltration starting at week 8 after treatment in the irradiated, vector-injected mice, but not in the nonirradiated, vector-injected mice (Figure 6b ). The number of these cells further increased at week 12 and remained significantly higher in the irradiated, vector-injected B10 BM recipients as compared with the nonirradiated, vector-injected mice (Figure 6b ).
We also examined the level of muscle infiltration of programmed death-1 (PD-1)-expressing cells, which have been shown to have immune regulatory effects. [34] [35] [36] There was no significant difference in the number of PD-1 + muscle-infiltrating cells in different treatment groups at different time points in mice receiving either low-dose or high-dose irradiation (data not shown).
Discussion
In studies on therapeutic gene replacement for DMD, the immune response of the dystrophic host to vector-mediated dystrophin protein expression is an important limiting factor with the potential to cause rejection of recombinant dystrophin. Further understanding of the immunological reactions against dystrophin, immune mechanisms that may modulate anti-dystrophin immunity, and manipulations that may reduce anti-dystrophin immune responses in a dystrophic host provides the potential to develop approaches designed to prolong dystrophin expression in the recipient of therapeutic gene transfer.
A temporal analysis of the effect of irradiation alone or irradiation combined with BM transfer on the immunity Dystrophin gene transfer to irradiated mdx mice S Eghtesad et al against vector-mediated full-length dystrophin expression in mdx muscle has not been previously reported. Previous studies have examined the effects on dystrophic muscle of adoptive transfer of wild-type BM to irradiated mdx mice, 37 muscle precursor cells to irradiated mdx mice, 38 or BMderived stem cells to nonirradiated mdx mice. 39 In the current study we limited the dose of irradiation to a maximum of 900 rad, as in other studies, 40 to avoid damage to muscle stem cells. 41 The use of the HC-Ad vector for gene delivery allowed exposure to all epitopes of an expressed full-length murine dystrophin cDNA. In our studies, BM transfer alone to mdx mice did not increase the level of muscle dystrophin expression over the background level in untreated mdx mice at any time point, which confirmed the findings of others. 37, 42 Therefore, the dystrophin expression observed after dystrophin vector delivery following irradiation and BM transfer is vector mediated.
Our findings demonstrate that irradiation of the dystrophic mdx host before intramuscular vector injection led to a delayed, reduced or absent humoral response against dystrophin protein. The changes in anti-dystrophin immunity in treated mice allowed us to study the progression of host immunity against dystrophin and its effect on dystrophin expression over a period of 12 weeks. The observation that both low-dose and high-dose irradiation delayed the development of an anti-dystrophin antibody response is significant compared with the previous findings of more rapid host immunity against dystrophin. 21 The delay in development of an anti-dystrophin humoral response was greater in the high-dose irradiated group compared with the low-dose irradiated group, as no anti-dystrophin humoral response was observed at 8 weeks after treatment. Our results suggest that the more complete immune cell depletion (both central and peripheral immune cells) and reconstitution with dystrophin-tolerant immune cells results in greater suppression of antidystrophin immunity induced by dystrophin gene transfer to the dystrophin-deficient mdx host.
The level of CD4 + and CD8 + T-cell infiltration in untreated dystrophic mdx muscle 31, 43 and in dystrophin vectorinjected mdx muscle 19, 44 has been previously investigated. The dystrophic pathology of mdx mouse muscle includes a high level of T-cell infiltration in the damaged tissue that is thought to promote the pathology associated with the disease. 31, 43 It has been shown that specific immune modulations that lead to absent or reduced T cells in the mdx mouse can ameliorate the disease process in muscle 31, 43, 45 and, in a gene transfer setting, reduce immunity against dystrophin protein in the host. 18, 44 Our present study compared the levels of infiltrating CD4 + and CD8 + T cells in vector-injected muscles with untreated mdx mouse muscle at different time points. Thus, we evaluated the role of these Tcell sub-populations in a gene therapy setting as both disease and the immunity against recombinant dystrophin progressed. In contrast to the observed correlation with the anti-dystrophin humoral response, irradiation before gene transfer does not seem to affect levels of infiltrating T cells in vector-injected muscles of the mdx host during 12 weeks after treatment, especially in the low-dose irradiation group. Interestingly, however, the pattern of T-cell infiltration in muscle tissue did appear to be affected by irradiation.
In the early stages after gene transfer, the finding of muscle fibers surrounded and invaded by T cells was only observed in the nonirradiated, vector-injected muscles. This focal pattern of T-cell infiltration was not observed in the irradiated vector-injected and untreated mdx mice at this time point. Double staining of T cells and dystrophin in the attacked fibers was not feasible because only necrotic fiber remnants remained. Nonetheless, the distinctive pattern of T-cell infiltration plus the absence of dystrophin-expressing fibers in nonirradiated, vector-injected muscles at early stages after gene transfer suggested that transduced fibers were targeted for immune attack. The same pattern of T-cell infiltration has also been observed in previous studies in which transfer of muscle precursor cells from dystrophinnormal donors to irradiated mdx mice, which had received mixed BM from muscle cell donors and mdx donors, resulted in infiltration of CD4 + and CD8 + T cells around dystrophin-expressing muscle fibers at 3-4 months after treatment. 46 Overall, our analysis of T-cell infiltration in treated mdx muscle indicates that even though CD4 + and CD8 + T-cell infiltrates are found in irradiated, vector-treated mdx muscles, this host immune response does not lead to an immediate rejection of dystrophin protein in the Dystrophin gene transfer to irradiated mdx mice S Eghtesad et al vector-injected muscles of irradiated mice for at least 12 weeks after treatment. In contrast, T-cell infiltration in the vector-injected muscles of nonirradiated mice appeared to reject dystrophin-expressing fibers, suggested by the pattern of T-cell infiltration surrounding muscle fibers and the absence of dystrophin expression as early as 4 weeks after treatment. This pattern of T-cell infiltration also correlated with the production of antidystrophin antibody production in these mice. One limitation of the analysis of cellular immunity observed in treated or untreated mdx muscle was that the antigens inducing immunity cannot be specifically determined.
To decipher the mechanism underlying the delayed and diminished host immune response observed in both low-and high-dose irradiated groups, we examined infiltration of Foxp3 + Treg cells and PD-1 + T cells in treated and control mdx muscles. Only Treg cells were different among the groups. We have previously observed Foxp3 + Treg cells to be at slightly higher levels in untreated mdx mouse muscle compared with agematched B10 muscle (SE and PRC, unpublished data). In this study, we observed even higher levels of Treg cells in vector-injected muscle of mdx mice 8 and 12 weeks after receiving high-dose irradiation and reconstitution of the immune system with B10 BM. This increase in Treg cells suggested their role in the diminished antidystrophin immune response observed in the setting of central and peripheral immune cell depletion followed by reconstitution. In contrast, Treg cells did not appear to have a role in the delayed immunity associated with depletion of the peripheral immune cells alone followed by self-reconstitution (low-dose irradiation). Taken together, these results suggest a role for Treg cells in the suppression of immunity induced by dystrophin vector gene transfer followed by reconstitution of the central immune system. The adoptive transfer of whole BM from B10 mice may have contributed to the relatively high level of Treg cells in treated muscles as the transferred BM is likely to contain cells tolerant to B10 self-antigens, including muscle proteins. The exact role of Treg cells in the setting of dystrophin gene delivery to dystrophic muscle will require further study.
In summary, we show that manipulation of the host immune system by irradiation of the adult dystrophic mdx mouse before intramuscular HC-Ad dystrophin vector delivery results in a delayed and diminished humoral immune response to vector-mediated dystrophin protein expression in the adult mdx mouse. The delay in the response correlated with a significantly slower rate of elimination of vector-mediated dystrophin protein expression in treated mdx muscle compared with muscle of nonirradiated vector-injected mice. Although there are technical limitations to determining the antigen specificity of T cells infiltrating muscle, the pattern of T cells surrounding and invading muscle fibers suggests that viral vector-mediated dystrophin transduction contributes to the antigenic targets, particularly as this pattern of T-cell infiltration is diminished and delayed by irradiation. The failure to eliminate anti-dystrophin humoral and T cell-mediated immunity with the central and peripheral immune depletion achieved by irradiation supports the contention that dystrophin expression in dystrophin-deficient, dystrophic muscle is immune stimulatory, a finding which has significant ramifications for dystrophin gene-replacement therapy.
Materials and methods
Mice
Wild-type (C57BL/10J) and mdx (C57BL/10ScSnDmd mdx/J) mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). All mouse studies were performed under approved protocols by the University of Pittsburgh Institutional Animal Care and Use Committee.
Dystrophin HC-Ad vector
The HC-Ad vector contains a full-length murine dystrophin cDNA under the control of the muscle creatine kinase promoter, the left and right viral inverted terminal repeats of adenovirus serotype 5 and hypoxanthineguanine phosphoribosyl transferase stuffer DNA. The construction of this vector has been fully described previously. 18, 47 
Mouse irradiation
Mice were irradiated at the age of 5-6 weeks in a linear accelerator (LINAC) irradiator (LINAC Technologies, Orsay, France) at either a low dose (600 rad) or a high dose (900 rad). Specialized care included autoclaved cages, autoclaved food and acidified water (pH 2.6) from the day before irradiation until the end of each study. In the low-dose irradiated group the immune system was allowed to spontaneously reconstitute following gene transfer and in the high-dose irradiated group the mice received whole BM from wild-type C57BL/10 mice at 12 h after gene transfer. BM was transferred by intravascular injections of 4.0-5.0 Â 10 6 cells.
Intramuscular vector injections
Irradiated and nonirradiated mice received inhalational anesthesia with isoflurane and were injected with 1.0-2.0 Â 10 10 genome copies of HC-AdmDYS vector intramuscularly in the TA muscle bilaterally. Each muscle was injected with a volume of 20 ml in phosphate-buffered saline (PBS), using a 28G needle (Becton Dickinson (BD), Franklin Lakes, NJ, USA).
Total muscle protein extract preparation
Freshly isolated mouse muscle was homogenized in lysis buffer (50 mM Tris-HCl, pH 8.0; 5 mM EGTA, pH 7.4; 5 mM EDTA, pH 8.0; 5% SDS) and incubated on ice for 45 min. Samples were then sonicated briefly and centrifuged at 14 000 r.p.m. for 20 min at 4 1C. Supernatant was collected and stored at À80 1C.
Serum preparation
Blood was collected by cardiac puncture shortly after euthanization and centrifuged at 10 000 r.p.m. for 15 min at 4 1C. Supernatant was collected and stored at 4 1C.
Gel electrophoresis and western blotting
The membranes with immobilized murine dystrophin protein used for the assay were generated from wildtype C57BL/10J (B10) total muscle protein extracts electrophoresed on SDS polyacrylamide gel electrophoresis. In brief, total muscle protein extracts from B10 mice were run on 5% acrylamide gel (Bio-Rad, Hercules, CA, USA) for 3 h at 110 V. Protein samples were transferred from the gel to nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA) for 1.5 h at 110 V at 4 1C. The membrane was blocked in 5% milk/1% sheep The membrane was then cut into pieces with a dystrophin protein band in each piece. The pieces of membrane were then each incubated with a diluted serum sample (1:300) in TBST for 1.5 h, then with horseradish peroxidase-conjugated sheep anti-mouse IgG (GE Healthcare, Piscataway, NJ, USA) diluted in TBST for 45 min at room temperature. ECL (enhanced chemiluminescence) detection reagent (GE Healthcare) was used to detect the chemiluminescent signal and Kodak film (Fisher, Pittsburgh, PA, USA) was used for visualizing the signal. A monoclonal anti-dystrophin antibody (Dys-2; Vector Laboratories, Burlingame, CA, USA) was used as a positive control. The presence or absence of a dystrophin band was recorded. The initial exposure time was 15-30 min, and to confirm the absence of a band in irradiated mice, an additional film was exposed to the membranes overnight.
BM preparation
Tibia and femur of adult wild-type mice were dissected with complete removal of surrounding muscle. Syringes with 26-G needles were used to flush the BM out of the bones onto a cell strainer using RPMI-1460 medium supplemented with 2% fetal bovine serum, 5% penicillin/streptomycin and 10 U ml -1 heparin (Sigma-Aldrich, St Louis, MO, USA). BM was then washed with a serum-free RPMI-1460 medium (5% penicillin/streptomycin, 20 mM HEPES) and counted. For adoptive transfer, cells were resuspended in serum-free medium at a concentration of 2.0 Â 10 7 cells per ml. Cell suspension (200 ml) was injected intravenously (4-5 Â 10 6 cells per mouse) using a 28-G needle (B-D).
Flow cytometry
Single-cell suspensions were prepared from lymph nodes by mechanical disaggregation through a 40-mm cell strainer (Fisher) into PBS. Cells were incubated with rat anti-CD4 (fluorescein isothiocyanate (FITC)), CD25 (Allophycocyanin (APC), and Foxp3 (phycoerythrin, (PE)) (eBiosciences, San Diego, CA, USA; 11-0042-82, 17-0251-81, 12-5773-80, respectively) and rat anti-CD8 (PE), CD19 (FITC), and CD11c (FITC) (Pharmingen, San Jose, CA, USA; 553032, 557398 and 557400, respectively) in fluorescence-activated cell sorting staining buffer (eBiosciences) as indicated by the manufacturer's instructions. The stained cells were then analyzed by a BD SLR II flow cytometer.
